New insight into the pathophysiology of lipid abnormalities in type 2 diabetes

Diabetes and Metabolism

Volumn 31, Issue 5, 2005, Pages 429-439

  Vergges B ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

HDL; LDL; Lipids; Lipoproteins; Type 2 diabetes; VLDL

Indexed keywords

ADIPOCYTOKINE; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPID TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; FATTY ACID OXIDATION; GLYCATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION KINETICS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 27844502475     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(07)70213-6     Document Type: Review

References (112)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
2. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524
3. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31
4. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979;59:8-13
5. Turner RC, Millns H, Neil HAW, et al. for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8
6. Olofsson SO, Stillemark-Billton P, Asp L. Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med. 2000;10:338-45
7. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes 1993;42:833-42
8. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Sherperd J, Taskinen MR. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998;47:779-87
9. Brunzell JD, Schwartz RS, Eckel RH, Goldberg AP. Insulin and adipose tissue lipoprotein lipase activity in humans. Int J Obes 1981;5:685-94
10. Fried SK, Russell CD, Grauso NL, Brolin RE. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 1993;92:2191-8
11. Chait A, Bierman EL, Albers JJ. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest 1979;64:1309-19
12. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984;33:333-8
13. Ruotolo G, Parlavecchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA, Ragogna F, Micossi P, Pozza G. Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 1994;17:6-12
14. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes 1999;48:1631-7
15. Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K. Suppression of plasma cholesteryl ester transfer protein activity in acute hyperinsulinemia and effect of plasma nonesterified fatty acid. Metabolism 1997;46:1166-70
16. Harris MI. Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes Care 1991;14:366-74
17. Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:341-5
18. UK Prospective Diabetes Study (UKPDS) XI. Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994;11:534-44
19. Reaven GM. Abnormal lipoprotein metabolism in non insulin-dependent diabetes mellitus. Am J Med 1987;83 (suppl. 3A):31-40
20. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992;41 (suppl. 2):12-17
21. Howard BV, Howard WJ. Dyslipidemia in non insulin-dependent diabetes mellitus. Endocrine Rev 1994;15:263-74
22. Tomkin GH, Owens D. Insulin and lipoprotein metabolism with special reference to the diabetic state. Diabetes Metab Rev 1994;10:225-52
23. Howard BV. Pathogenesis of diabetic dyslipidemia. Diabetes Rev 1995;3:423-32
24. Lopes-Virella MF, Klein RL, Virella G. Modification of lipoproteins in diabetes. Diabetes Metab Rev 1996;12:69-90
25. Verges B. Dyslipidemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999;25 (Suppl 3):32-40
26. Steiner G. The dyslipoproteinemias of diabetes. Atherosclerosis 1994;110 (suppl.):27-33.
27. Steiner G, Tkac I, Uffelman KD, Lewis GF. Important contribution of lipoprotein particle number to plasma triglyceride concentration in type 2 diabetes. Atherosclerosis 1998;137:211-14
28. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in non insulin dependent diabetes mellitus. Diabetes 1982;31:217-25
29. Reaven GM, Greenfield DS. Diabetic hypertriglyceridemia. Evidence for three clinical syndromes. Diabetes 1981;30 (suppl. 2):66-75
30. Tobey TA, Greenfield DS, Kramer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic man. Metabolism 1981;30:165-71
31. Malmström R, Packard LJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-62
32. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-9
33. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77-86
34. Tobe K, Suzuki R, Aoyama M, et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-(2-/-) mouse liver. J Biol Chem 2001;276:38337-40
35. Cummings MH, Watts GF, Umpleby AM, et al. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995;44:1059-65
36. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994;1215:9-32
37. Theriault A, Cheung R, Adeli K. Expression of apolipoprotein B in vitro in cell-free lysates of HepG2 cells: evidence that insulin modulates ApoB synthesis at the translational level. Clin Biochem 1992;25:321-3
38. Chireac DV, Chireac LR, Corsetti JP, et al. Glucose-stimulated insulin secretion supresses hepatic triglyceride-rich lipoprotein and apob production. Am J Endocrinol Metab 2000;279:E1003-E1011
39. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J 1996;313:567-74
40. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem 1997;272:30693-702
41. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HEPG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 1995;36:1073-81
42. Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000;275:8416-25
43. Bartels ED, Lauritsen M, Nielsen LB. Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 2002;51:1233-9
44. Pont F, Duvillard L, Florentin E, Gambert P, Verges B. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 2002;22:1726-32
45. Howard BV, Abbott WG, Beltz WF, et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non insulin dependent diabetes. Metabolism 1987;36:870-7
46. Taskinen MR, Beltz WF, Harper I, et al. The effects of non insulin-dependent diabetes mellitus on VLDL triglyceride and VLDL apoB metabolism: studies before and after sulfonlyurea therapy. Diabetes 1986;35:1268-77
47. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000;30:685-94
48. Taskinen MR, Nikkila EA, Kuusi T, Harno K. Lipoprotein lipase activity and serum lipoproteins in untreated type 2 diabetes associated with obesity. Diabetologia 1982;22:46-50
49. Panarotto D, Remillard P, Bouffard L, Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002;32:84-92
50. De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996;26:89-108
51. Syvanne M, Hilden H, Taskinen MR. Abnormal metabolism of post-prandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 1994;35:15-26
52. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49
53. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002;18:484-90
54. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001;17:27-43
55. Gianturco SH, Bradley WA, Gotto AM Jr, Morrisett JD, Peavy DL. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J Clin Invest 1982;70:168-78
56. Mamo JCL, Szeto L, Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990;33:339-42
57. Saheki S, Hitsumoto Y, Murase M, Takeuchi N, Uchida K. In vitro degradation of very low density lipoprotein from diabetic patients by lipoprotein lipase. Clin Chim Acta 1993;217:105-14
58. Duvillard L, Pont F, Florentin E, Gambert P, Verges B. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 2000;43:27-35
59. Duvillard L, Florentin E, Lizard G, et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003;26:1540-4
60. Witzum JL, Mahoney EM, Bronks MJ, et al. Non enzymatic glucosylation of low density lipoprotein alters its biologic activity. Diabetes 1982;31:283-91
61. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non insulin dependent diabetes. Arterioscler Thromb 1992;12:1496-502
62. Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in man. Diabetes Care 1994;17:1164-1171
63. Lamdenpera S, Sane T, Vuorinen-Markkola H, Knudsen P, Taskinen MR. LDL particle sizes in midly hypertriglyceridemic subjects: no relation to insulin-resistance or diabetes. Atherosclerosis 1995;113:227-36
64. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506
65. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75
66. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81
67. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998;19 Suppl A:A24-30.
68. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996;124:261-71
69. Vakkilainen J, Makimattila S, Seppala-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation 2000;102:716-21
70. Makimattila S, Liu ML, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999;22:973-81
71. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-99
72. Cominacini L, Garbin U, Pastorino AM, et al. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 1994;26:173-84
73. B. Verges, Galland F, Duvillard L, et al. Direct measurement of plasma oxidized LDL levels in type 2 diabetic patients before and after insulin therapy. Diabetologia 2003;46 (Suppl 2):73 [Abstract]
74. De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298-306
75. Kim HJ, Kurup IV. Non enzymatic glycosylation of human plusma low density lipoprotein. Evidence for in vitro and in vivo glucosylation. Metabolism 1982;31:348-53
76. Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 1997;8:174-80
77. Steinbrecher UP, Witzum JL. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984;33:130-4
78. Hunt JV, Smith CCT, Wolff SP. Autointoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990;39:1420-4
79. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7
80. Taskinen MR, Harno K, Nikkila EA. Serum lipids and lipoproteins in type 2 diabetes. Acta Endocrinol (Kbh) 1984;262(suppl):95-9
81. Verges B, Brun JM, Vaillant G, et al. Influence of obesity and hypertriglyceridemia on low HDL2-cholesterol level and its relationship with prevalence of atherosclerosis in type 2 diabetes. Diabetes Metab 1992;18:289-97
82. Golay A, Zech L, Shi MZ, et al. High density lipoprotein (HDL) metabolism in non insulin dependent diabetes mellitus: measurement of HDL turn-over using tritiated HDL. J Clin Endocrinol Metab 1987;65:512-8
83. Duvillard L, Pont F, Florentin E, Gambert P, Verges B. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non insulin-dependent diabetes mellitus. Atherosclerosis 2000;152:229-37
84. Nikkila EA, Huttunen JK, Ehnholm C. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes 1977;26:11-21
85. Verges B, Duvillard L, Pont F, Florentin E, Gambert P. Respective effects of insulin resistance and "relative" insulin deficiency on apoB and apoA1 metabolism in NIDDM. Diabetologia 2000;43(suppl 1): A38 [Abstract]
86. Pont F, Duvillard L, Florentin E, Gambert P, Verges B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord 2002;26:1151-8
87. Caste C, Kuiper S, Blake W, Paigen B, Marotti K, Melchior G. Remodeling of the HDL in NIDDM a fundamental role for cholesteryl ester transfer protein. Am J Physiol 1998;274:E1091-8
88. Calvo C, Talussot C, Ponsin G, Berthezène F. Non enzymatic glycation of apolipoprotein A1. Effects on its self-association and lipid binding properties. Biochem Biophys Res Com 1988;533:1060-7
89. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991;40:377-84
90. Cavallero E, Brites F, Delfly B, et al. Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 1995;15:2130-5
91. Quintao EC, Medina WL, Passarelli M. Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 2000;16:237-250
92. Syvanne M, Castro G, Dengremont C, et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996;127:245-53
93. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in non insulin-dependent diabetes mellitus. Atherosclerosis 1993;104:69-77
94. Riemens S, Vantoll A, Sluiter W, Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM relationships with apo B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-9
95. Ahnadi CE, Masmoudi T, Berthezène F, Ponsin G. Decreased ability of high density lipoproteins to transfer cholesterol esters in non insulin-dependent diabetes mellitus. Eur J Clin Invest 1993;23:459-65
96. Passarelli M, Catanozi S, Nakandakare ER, Rocha JC, Morton RE, Shimabukuro AF, Quintao EC. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 1997;40:1085-93
97. Desrumaux C, Athias A, Bessede G, et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999;19:266-75
98. Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol 2004;82:170-90
99. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 1998;273:16710-4
100. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6
101. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83
102. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5
103. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004;27:1680-7
104. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent role of age and sex. Diabetologia 2003;46:459-69
105. Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003;52:239-43
106. Shetty G, Economides P, Horton E, Mantzoros C, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7
107. Ng T, Watts G, Farvid M, Chan D, Barrett PH. Adipocytokines and VLDL metabolism. Independent regulatory effects of adiponectin, insulin resistance and fat compartments on VLDL apoB-100 kinetics? Diabetes 2005;54:795-802
108. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95
109. Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004;145:367-83
110. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003;14:447-55
111. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999;10:19-29
112. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, Barren PH. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprtein metabolism. Clin Chem 2005;51:578-85